25 XP   0   0   10

Kiora Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Kiora Pharmaceuticals Inc together

PenkeI guess you are interested in Kiora Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Kiora Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Kiora Pharmaceuticals Inc

I send you an email if I find something interesting about Kiora Pharmaceuticals Inc.

Quick analysis of Kiora Pharmaceuticals Inc (30 sec.)










What can you expect buying and holding a share of Kiora Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
2.5%

What is your share worth?

Current worth
$0.23
Expected worth in 1 year
$0.03
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
$-0.20
Return On Investment
-42.0%

For what price can you sell your share?

Current Price per Share
$0.48
Expected price per share
$0.462 - $0.5339
How sure are you?
50%

1. Valuation of Kiora Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)

$0.48

Intrinsic Value Per Share

$-4.55 - $-3.77

Total Value Per Share

$-4.31 - $-3.54

2. Growth of Kiora Pharmaceuticals Inc (5 min.)




Is Kiora Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$6.1m$10.6m-$1m-11.6%

How much money is Kiora Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$3.2m-$5.2m$2m64.5%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Kiora Pharmaceuticals Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#722 / 1010

Most Revenue
#763 / 1010

Most Profit
#363 / 1010

Most Efficient
#195 / 1010

What can you expect buying and holding a share of Kiora Pharmaceuticals Inc? (5 min.)

Welcome investor! Kiora Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Kiora Pharmaceuticals Inc.

What can you expect buying and holding a share of Kiora Pharmaceuticals Inc?

First you should know what it really means to hold a share of Kiora Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Kiora Pharmaceuticals Inc is $0.48. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Kiora Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Kiora Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.23. Based on the TTM, the Book Value Change Per Share is $-0.05 per quarter. Based on the YOY, the Book Value Change Per Share is $0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Kiora Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.09-18.0%-0.13-26.3%-0.13-27.2%-0.11-22.2%-0.10-20.5%
Usd Book Value Change Per Share-0.08-15.8%-0.05-10.5%0.024.3%-0.01-1.1%0.048.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.011.6%
Usd Total Gains Per Share-0.08-15.8%-0.05-10.5%0.024.3%-0.01-1.1%0.0510.4%
Usd Price Per Share0.52-1.27-2.67-3.04-2.29-
Price to Earnings Ratio-1.51--3.04--4.73--7.56--5.93-
Price-to-Total Gains Ratio-6.87--18.69--37.19--0.12--13.01-
Price to Book Ratio2.24-3.49-6.53-9.56-7.25-
Price-to-Total Gains Ratio-6.87--18.69--37.19--0.12--13.01-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.48
Number of shares2083
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.05-0.01
Usd Total Gains Per Share-0.05-0.01
Gains per Quarter (2083 shares)-105.08-11.21
Gains per Year (2083 shares)-420.31-44.85
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-420-4300-45-55
20-841-8500-90-100
30-1261-12700-135-145
40-1681-16900-179-190
50-2102-21100-224-235
60-2522-25300-269-280
70-2942-29500-314-325
80-3362-33700-359-370
90-3783-37900-404-415
100-4203-42100-448-460

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%2.038.00.05.0%2.039.00.04.9%
Book Value Change Per Share1.03.00.025.0%5.06.01.041.7%9.010.01.045.0%16.023.01.040.0%16.024.01.039.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%1.00.039.02.5%1.00.040.02.4%
Total Gains per Share1.03.00.025.0%5.06.01.041.7%9.010.01.045.0%16.023.01.040.0%16.024.01.039.0%

Fundamentals of Kiora Pharmaceuticals Inc

About Kiora Pharmaceuticals Inc

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

Fundamental data was last updated by Penke on 2024-04-21 23:41:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Kiora Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Kiora Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Kiora Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Kiora Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-1,000.0%+1,000.0%
5Y-1,000.0%10Y-922.4%-77.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.2%+207.2%
TTM--216.8%+216.8%
YOY--282.3%+282.3%
5Y-1,000.0%-436.8%-563.2%
10Y-922.4%-597.3%-325.1%
1.1.2. Return on Assets

Shows how efficient Kiora Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Kiora Pharmaceuticals Inc to the Biotechnology industry mean.
  • -16.5% Return on Assets means that Kiora Pharmaceuticals Inc generated $-0.17 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Kiora Pharmaceuticals Inc:

  • The MRQ is -16.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -19.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-16.5%TTM-19.9%+3.3%
TTM-19.9%YOY-29.5%+9.7%
TTM-19.9%5Y-21.3%+1.4%
5Y-21.3%10Y-29.4%+8.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-16.5%-13.3%-3.2%
TTM-19.9%-12.8%-7.1%
YOY-29.5%-11.6%-17.9%
5Y-21.3%-13.8%-7.5%
10Y-29.4%-15.6%-13.8%
1.1.3. Return on Equity

Shows how efficient Kiora Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Kiora Pharmaceuticals Inc to the Biotechnology industry mean.
  • -37.1% Return on Equity means Kiora Pharmaceuticals Inc generated $-0.37 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Kiora Pharmaceuticals Inc:

  • The MRQ is -37.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -37.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-37.1%TTM-37.4%+0.2%
TTM-37.4%YOY-52.1%+14.8%
TTM-37.4%5Y-37.0%-0.3%
5Y-37.0%10Y-52.6%+15.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-37.1%-16.9%-20.2%
TTM-37.4%-16.1%-21.3%
YOY-52.1%-14.9%-37.2%
5Y-37.0%-19.3%-17.7%
10Y-52.6%-20.1%-32.5%

1.2. Operating Efficiency of Kiora Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Kiora Pharmaceuticals Inc is operating .

  • Measures how much profit Kiora Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Kiora Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Kiora Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-993.3%+993.3%
5Y-993.3%10Y-919.0%-74.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--298.0%+298.0%
TTM--238.5%+238.5%
YOY--288.4%+288.4%
5Y-993.3%-486.2%-507.1%
10Y-919.0%-628.4%-290.6%
1.2.2. Operating Ratio

Measures how efficient Kiora Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Kiora Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y10.506-10.506
5Y10.50610Y9.709+0.798
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.235-3.235
TTM-3.310-3.310
YOY-3.838-3.838
5Y10.5065.679+4.827
10Y9.7097.823+1.886

1.3. Liquidity of Kiora Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Kiora Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.90 means the company has $2.90 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Kiora Pharmaceuticals Inc:

  • The MRQ is 2.900. The company is able to pay all its short-term debts. +1
  • The TTM is 3.405. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.900TTM3.405-0.506
TTM3.405YOY3.186+0.219
TTM3.4055Y4.117-0.712
5Y4.11710Y2.948+1.169
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.9003.863-0.963
TTM3.4054.169-0.764
YOY3.1865.337-2.151
5Y4.1176.122-2.005
10Y2.9486.434-3.486
1.3.2. Quick Ratio

Measures if Kiora Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Kiora Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 2.76 means the company can pay off $2.76 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Kiora Pharmaceuticals Inc:

  • The MRQ is 2.757. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.249. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.757TTM3.249-0.492
TTM3.249YOY2.951+0.298
TTM3.2495Y3.523-0.274
5Y3.52310Y2.602+0.921
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.7573.504-0.747
TTM3.2493.991-0.742
YOY2.9515.371-2.420
5Y3.5236.088-2.565
10Y2.6026.395-3.793

1.4. Solvency of Kiora Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Kiora Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Kiora Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.55 means that Kiora Pharmaceuticals Inc assets are financed with 55.4% credit (debt) and the remaining percentage (100% - 55.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Kiora Pharmaceuticals Inc:

  • The MRQ is 0.554. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.436. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.554TTM0.436+0.118
TTM0.436YOY0.411+0.025
TTM0.4365Y0.380+0.056
5Y0.38010Y4.205-3.825
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5540.339+0.215
TTM0.4360.337+0.099
YOY0.4110.271+0.140
5Y0.3800.368+0.012
10Y4.2050.388+3.817
1.4.2. Debt to Equity Ratio

Measures if Kiora Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Kiora Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 124.4% means that company has $1.24 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Kiora Pharmaceuticals Inc:

  • The MRQ is 1.244. The company is able to pay all its debts with equity. +1
  • The TTM is 0.823. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ1.244TTM0.823+0.422
TTM0.823YOY0.710+0.113
TTM0.8235Y0.655+0.168
5Y0.65510Y1.177-0.522
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2440.392+0.852
TTM0.8230.403+0.420
YOY0.7100.335+0.375
5Y0.6550.427+0.228
10Y1.1770.461+0.716

2. Market Valuation of Kiora Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Kiora Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Kiora Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -1.51 means the investor is paying $-1.51 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Kiora Pharmaceuticals Inc:

  • The EOD is -1.389. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.510. Based on the earnings, the company is expensive. -2
  • The TTM is -3.040. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.389MRQ-1.510+0.122
MRQ-1.510TTM-3.040+1.530
TTM-3.040YOY-4.733+1.693
TTM-3.0405Y-7.562+4.522
5Y-7.56210Y-5.927-1.634
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.389-2.300+0.911
MRQ-1.510-2.656+1.146
TTM-3.040-2.718-0.322
YOY-4.733-4.145-0.588
5Y-7.562-6.258-1.304
10Y-5.927-6.315+0.388
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Kiora Pharmaceuticals Inc:

  • The EOD is -1.221. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.327. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.249. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.221MRQ-1.327+0.107
MRQ-1.327TTM-3.249+1.922
TTM-3.249YOY-6.622+3.373
TTM-3.2495Y-8.878+5.629
5Y-8.87810Y-32.338+23.460
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.221-2.974+1.753
MRQ-1.327-3.306+1.979
TTM-3.249-3.508+0.259
YOY-6.622-5.613-1.009
5Y-8.878-8.378-0.500
10Y-32.338-8.873-23.465
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Kiora Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.24 means the investor is paying $2.24 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Kiora Pharmaceuticals Inc:

  • The EOD is 2.063. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.243. Based on the equity, the company is underpriced. +1
  • The TTM is 3.489. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.063MRQ2.243-0.180
MRQ2.243TTM3.489-1.246
TTM3.489YOY6.528-3.039
TTM3.4895Y9.558-6.069
5Y9.55810Y7.253+2.306
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.0631.914+0.149
MRQ2.2432.116+0.127
TTM3.4892.097+1.392
YOY6.5282.881+3.647
5Y9.5583.550+6.008
10Y7.2533.936+3.317
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Kiora Pharmaceuticals Inc.

3.1. Institutions holding Kiora Pharmaceuticals Inc

Institutions are holding 17.607% of the shares of Kiora Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31CapTrust Financial Advisors0.34060.00018000000
2023-12-31Geode Capital Management, LLC0.158403721100
2023-12-31Virtu Financial LLC0.12110.001228441284410
2023-12-31Vanguard Group Inc0.104602456614063133.8951
2023-12-31Renaissance Technologies Corp0.0796018700187000
2023-12-31BlackRock Inc0.061601446200
2023-12-31Tower Research Capital LLC0.017804173-14-0.3344
2023-12-31UBS Group AG0.00940221174350.6131
2023-12-31Goss Wealth Management LLC0.0009020000
2023-12-31U.S. Bancorp0.000306700
2023-12-31Wells Fargo & Co0.0003059-54-47.7876
2023-12-31Advisor Group Holdings, Inc.0.000203600
2023-12-31Morgan Stanley - Brokerage Accounts00800
2023-12-31Albion Financial Group (Utah)00600
2023-09-30Sabby Management LLC000-312369-100
2023-12-31FMR Inc000-2-100
2023-12-31XTX Topco Ltd000-11790-100
2023-09-30TWO SIGMA SECURITIES, LLC000-12331-100
2023-09-30Walleye Trading Advisors, LLC000-250258-100
2023-09-30HRT FINANCIAL LLC000-13469-100
Total 0.89480.0013210140-538340-256.2%

3.2. Funds holding Kiora Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Fidelity Extended Market Index0.13350.000135051-170-0.4827
2024-03-31Vanguard Institutional Extnd Mkt Idx Tr0.093602456600
2023-09-30BlackRock Extended Mkt Composite0.05310.00011393800
2024-03-31BlackRock Extended Equity Market K0.04630.00011216440.0329
2024-02-29Fidelity Series Total Market Index0.00740194400
2024-03-31Extended Equity Market Fund M0.00570.00011501-3-0.1995
2024-02-29Spartan Extended Market Index Pool E0.00080216170369.5652
2024-03-31NT Ext Equity Mkt Idx Fd - L0.0004011800
2023-12-31Northern Trust Extended Eq Market Idx0.0004011800
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.000409800
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.000307900
2024-03-31State St US Extended Mkt Indx NL Cl C0.000204900
2023-12-31SSgA U.S. Extended Market Index Class I0.000204900
2023-12-31SSgA U.S. Total Market Index Strategy0.000101400
2023-12-31NT US Market Cap Idx Fd - L00500
2023-12-31NT Ext Eq Mkt Indx Fd DC Lending Tier 500300
Total 0.34240.000489913+1+0.0%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Kiora Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.076-0.050-34%0.021-465%-0.005-93%0.042-280%
Book Value Per Share--0.2330.362-36%0.404-42%0.363-36%0.102+129%
Current Ratio--2.9003.405-15%3.186-9%4.117-30%2.948-2%
Debt To Asset Ratio--0.5540.436+27%0.411+35%0.380+46%4.205-87%
Debt To Equity Ratio--1.2440.823+51%0.710+75%0.655+90%1.177+6%
Dividend Per Share----0%-0%-0%0.008-100%
Eps---0.086-0.126+46%-0.130+51%-0.106+23%-0.099+14%
Free Cash Flow Per Share---0.098-0.091-7%-0.107+9%-0.090-8%-0.075-24%
Free Cash Flow To Equity Per Share---0.117-0.034-71%0.029-509%0.000-100%0.009-1338%
Gross Profit Margin--0.9970.9990%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---3.771--------
Intrinsic Value_10Y_min---4.547--------
Intrinsic Value_1Y_max---0.311--------
Intrinsic Value_1Y_min---0.415--------
Intrinsic Value_3Y_max---0.985--------
Intrinsic Value_3Y_min---1.289--------
Intrinsic Value_5Y_max---1.721--------
Intrinsic Value_5Y_min---2.204--------
Market Cap12602976.000-9%13705736.40033299425.650-59%70058105.650-80%79741392.210-83%60189712.880-77%
Net Profit Margin----0%-0%-10.0000%-9.2240%
Operating Margin----0%-0%-9.9330%-9.1900%
Operating Ratio----0%-0%10.506-100%9.709-100%
Pb Ratio2.063-9%2.2433.489-36%6.528-66%9.558-77%7.253-69%
Pe Ratio-1.389+8%-1.510-3.040+101%-4.733+213%-7.562+401%-5.927+292%
Price Per Share0.480-9%0.5221.268-59%2.668-80%3.037-83%2.292-77%
Price To Free Cash Flow Ratio-1.221+8%-1.327-3.249+145%-6.622+399%-8.878+569%-32.338+2336%
Price To Total Gains Ratio-6.319+8%-6.872-18.691+172%-37.193+441%-0.119-98%-13.011+89%
Quick Ratio--2.7573.249-15%2.951-7%3.523-22%2.602+6%
Return On Assets---0.165-0.199+20%-0.295+79%-0.213+29%-0.294+77%
Return On Equity---0.371-0.374+1%-0.521+40%-0.3700%-0.526+42%
Total Gains Per Share---0.076-0.050-34%0.021-465%-0.005-93%0.050-252%
Usd Book Value--6109654.0009502871.750-36%10602861.000-42%9527795.100-36%2665388.950+129%
Usd Book Value Change Per Share---0.076-0.050-34%0.021-465%-0.005-93%0.042-280%
Usd Book Value Per Share--0.2330.362-36%0.404-42%0.363-36%0.102+129%
Usd Dividend Per Share----0%-0%-0%0.008-100%
Usd Eps---0.086-0.126+46%-0.130+51%-0.106+23%-0.099+14%
Usd Free Cash Flow---2581341.000-2389237.750-7%-2818867.250+9%-2363751.800-8%-1961976.350-24%
Usd Free Cash Flow Per Share---0.098-0.091-7%-0.107+9%-0.090-8%-0.075-24%
Usd Free Cash Flow To Equity Per Share---0.117-0.034-71%0.029-509%0.000-100%0.009-1338%
Usd Market Cap12602976.000-9%13705736.40033299425.650-59%70058105.650-80%79741392.210-83%60189712.880-77%
Usd Price Per Share0.480-9%0.5221.268-59%2.668-80%3.037-83%2.292-77%
Usd Profit---2268606.000-3220904.250+42%-5299667.750+134%-3283292.150+45%-2830144.025+25%
Usd Revenue----0%-0%134902.950-100%135683.900-100%
Usd Total Gains Per Share---0.076-0.050-34%0.021-465%-0.005-93%0.050-252%
 EOD+3 -5MRQTTM+8 -22YOY+11 -195Y+7 -2510Y+14 -20

4.2. Fundamental Score

Let's check the fundamental score of Kiora Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.389
Price to Book Ratio (EOD)Between0-12.063
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.757
Current Ratio (MRQ)Greater than12.900
Debt to Asset Ratio (MRQ)Less than10.554
Debt to Equity Ratio (MRQ)Less than11.244
Return on Equity (MRQ)Greater than0.15-0.371
Return on Assets (MRQ)Greater than0.05-0.165
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Kiora Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.109
Ma 20Greater thanMa 500.563
Ma 50Greater thanMa 1000.606
Ma 100Greater thanMa 2000.594
OpenGreater thanClose0.491
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets13,712
Total Liabilities7,602
Total Stockholder Equity6,110
 As reported
Total Liabilities 7,602
Total Stockholder Equity+ 6,110
Total Assets = 13,712

Assets

Total Assets13,712
Total Current Assets4,738
Long-term Assets8,974
Total Current Assets
Cash And Cash Equivalents 2,455
Net Receivables 2,050
Inventory 0
Other Current Assets 233
Total Current Assets  (as reported)4,738
Total Current Assets  (calculated)4,738
+/-0
Long-term Assets
Property Plant Equipment 115
Intangible Assets 8,814
Long-term Assets Other 41
Long-term Assets  (as reported)8,974
Long-term Assets  (calculated)8,970
+/- 4

Liabilities & Shareholders' Equity

Total Current Liabilities1,634
Long-term Liabilities5,968
Total Stockholder Equity6,110
Total Current Liabilities
Short-term Debt 47
Accounts payable 206
Other Current Liabilities 1,381
Total Current Liabilities  (as reported)1,634
Total Current Liabilities  (calculated)1,634
+/-0
Long-term Liabilities
Capital Lease Obligations 107
Long-term Liabilities Other 5,129
Long-term Liabilities  (as reported)5,968
Long-term Liabilities  (calculated)5,236
+/- 732
Total Stockholder Equity
Common Stock77
Retained Earnings -146,977
Accumulated Other Comprehensive Income -183
Other Stockholders Equity 153,192
Total Stockholder Equity (as reported)6,110
Total Stockholder Equity (calculated)6,110
+/- 0
Other
Capital Stock77
Cash and Short Term Investments 2,455
Common Stock Shares Outstanding 7,706
Liabilities and Stockholders Equity 13,712
Net Debt -2,348
Net Invested Capital 6,110
Net Working Capital 3,104
Property Plant and Equipment Gross 121
Short Long Term Debt Total 107



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-31
> Total Assets 
0
0
0
692
674
1,104
1,610
1,406
2,547
1,556
10,086
9,508
12,317
12,783
10,617
9,731
12,001
18,313
16,059
14,305
11,166
19,065
16,652
14,281
12,439
10,896
8,868
10,113
12,187
10,967
9,245
15,158
20,621
18,100
25,493
18,058
18,058
17,636
17,662
18,678
16,528
19,885
15,896
13,712
13,71215,89619,88516,52818,67817,66217,63618,05818,05825,49318,10020,62115,1589,24510,96712,18710,1138,86810,89612,43914,28116,65219,06511,16614,30516,05918,31312,0019,73110,61712,78312,3179,50810,0861,5562,5471,4061,6101,104674692000
   > Total Current Assets 
0
0
0
559
580
495
352
219
2,489
1,430
10,029
9,449
8,327
8,776
6,263
4,154
6,429
12,446
10,229
8,459
5,328
13,235
10,581
8,478
6,659
5,128
3,113
4,324
6,394
5,197
3,498
1,810
6,991
4,415
11,870
8,991
8,991
6,550
6,624
7,681
5,618
9,023
6,983
4,738
4,7386,9839,0235,6187,6816,6246,5508,9918,99111,8704,4156,9911,8103,4985,1976,3944,3243,1135,1286,6598,47810,58113,2355,3288,45910,22912,4466,4294,1546,2638,7768,3279,44910,0291,4302,489219352495580559000
       Cash And Cash Equivalents 
0
0
0
501
523
402
311
167
2,285
1,274
9,919
8,394
7,215
8,026
5,682
3,635
5,438
11,763
9,245
7,806
3,648
12,605
9,900
8,004
5,856
4,465
2,455
3,777
5,878
4,689
2,931
1,186
6,610
3,663
11,107
7,855
7,855
5,067
4,802
5,965
3,426
7,952
5,400
2,455
2,4555,4007,9523,4265,9654,8025,0677,8557,85511,1073,6636,6101,1862,9314,6895,8783,7772,4554,4655,8568,0049,90012,6053,6487,8069,24511,7635,4383,6355,6828,0267,2158,3949,9191,2742,285167311402523501000
       Net Receivables 
0
0
0
35
39
70
25
25
23
23
25
933
364
73
53
54
128
164
624
24
948
15
17
18
7
2
4
5
5
2
3
91
147
311
421
530
530
552
1,563
1,373
1,703
805
1,343
2,050
2,0501,3438051,7031,3731,563552530530421311147913255427181715948246241641285453733649332523232525703935000
       Other Current Assets 
0
0
0
22
18
23
16
26
181
134
84
122
749
677
527
465
863
520
360
630
732
615
664
456
97
661
654
543
511
507
563
533
233
441
342
0
607
930
126
343
89
68
73
233
233736889343126930607034244123353356350751154365466197456664615732630360520863465527677749122841341812616231822000
   > Long-term Assets 
0
0
0
134
94
609
1,257
1,188
58
126
57
59
3,989
4,007
4,354
5,577
5,572
5,867
5,831
5,846
5,838
5,830
6,071
5,802
5,781
5,768
5,755
5,788
5,793
5,769
5,747
13,347
13,630
13,685
13,623
9,067
9,067
11,086
11,038
10,998
10,910
10,862
8,913
8,974
8,9748,91310,86210,91010,99811,03811,0869,0679,06713,62313,68513,63013,3475,7475,7695,7935,7885,7555,7685,7815,8026,0715,8305,8385,8465,8315,8675,5725,5774,3544,0073,9895957126581,1881,25760994134000
       Property Plant Equipment 
0
0
0
3
2
2
2
1
1
1
0
0
1
0
43
38
34
29
24
56
48
40
50
44
37
30
24
17
16
14
11
31
327
392
338
283
283
226
207
172
136
95
57
115
115579513617220722628328333839232731111416172430374450404856242934384301001112223000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,438
5,438
5,438
5,438
5,438
5,438
5,438
1,526
1,526
1,526
1,526
1,526
1,526
1,526
1,526
1,526
3,485
3,485
3,485
3,485
0
0
0
0
0
0
0
0
0
0000000003,4853,4853,4853,4851,5261,5261,5261,5261,5261,5261,5261,5261,5265,4385,4385,4385,4385,4385,4385,438000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
3,912
4,212
5,438
5,438
5,438
5,438
5,438
0
0
4,162
4,156
4,150
4,144
4,137
4,131
4,125
4,119
4,112
9,730
9,724
9,718
9,711
8,696
8,696
10,762
10,749
10,743
10,737
10,731
8,820
8,814
8,8148,82010,73110,73710,74310,74910,7628,6968,6969,7119,7189,7249,7304,1124,1194,1254,1314,1374,1444,1504,1564,162005,4385,4385,4385,4385,4384,2123,9120000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,010
9,638
9,630
9,627
89
10,687
99
89
82
0
0
37
0
0
00370082899910,687899,6279,6309,6384,010000000000000000000000000000000
> Total Liabilities 
0
0
0
38,980
39,696
41,253
41,253
41,433
413
643
1,409
3,421
5,650
6,315
7,371
10,060
13,148
13,744
15,380
16,232
5,888
5,516
5,552
5,344
2,400
2,424
3,656
3,490
2,870
3,169
3,284
8,158
7,936
7,646
8,145
8,833
8,833
6,378
7,141
7,271
6,372
6,243
7,792
7,602
7,6027,7926,2436,3727,2717,1416,3788,8338,8338,1457,6467,9368,1583,2843,1692,8703,4903,6562,4242,4005,3445,5525,5165,88816,23215,38013,74413,14810,0607,3716,3155,6503,4211,40964341341,43341,25341,25339,69638,980000
   > Total Current Liabilities 
0
0
0
2,571
3,288
4,845
4,844
5,024
413
643
1,409
3,421
5,650
5,105
6,161
7,308
10,399
10,999
12,637
14,834
4,491
4,121
4,158
3,864
920
944
2,176
1,415
794
816
930
1,772
1,426
1,436
1,959
1,610
1,610
2,521
2,994
3,272
2,156
1,883
2,101
1,634
1,6342,1011,8832,1563,2722,9942,5211,6101,6101,9591,4361,4261,7729308167941,4152,1769449203,8644,1584,1214,49114,83412,63710,99910,3997,3086,1615,1055,6503,4211,4096434135,0244,8444,8453,2882,571000
       Short-term Debt 
0
0
0
2,027
2,473
2,422
2,842
3,206
0
0
0
0
911
0
32
13
13
13
13
11
10
8
6
5
3
111
126
84
145
103
62
48
83
170
145
0
119
92
131
106
73
39
19
47
4719397310613192119014517083486210314584126111356810111313131332091100003,2062,8422,4222,4732,027000
       Accounts payable 
0
0
0
14
8
230
276
566
286
338
158
418
869
1,230
1,403
1,412
1,311
971
659
706
222
356
324
64
244
97
1,068
210
158
94
60
435
457
292
425
161
161
302
749
1,008
587
131
125
206
2061251315871,00874930216116142529245743560941582101,06897244643243562227066599711,3111,4121,4031,230869418158338286566276230814000
       Other Current Liabilities 
0
0
0
530
806
1,152
488
303
127
305
251
1,096
1,210
1,312
1,308
1,658
850
1,154
1,712
1,803
1,400
1,034
1,141
1,110
98
736
983
1,120
491
619
809
1,289
885
974
1,389
0
1,330
2,127
2,114
2,158
1,495
314
495
1,381
1,3814953141,4952,1582,1142,1271,33001,3899748851,2898096194911,120983736981,1101,1411,0341,4001,8031,7121,1548501,6581,3081,3121,2101,0962513051273034881,152806530000
   > Long-term Liabilities 
0
0
0
36,409
36,409
36,409
36,409
36,409
0
0
0
0
0
1,210
1,210
2,752
2,749
2,746
2,742
1,399
1,397
1,396
1,394
1,480
1,480
1,480
1,480
2,075
2,075
2,354
2,354
6,386
6,510
6,210
6,186
7,224
7,224
3,857
4,146
3,998
4,216
4,359
5,692
5,968
5,9685,6924,3594,2163,9984,1463,8577,2247,2246,1866,2106,5106,3862,3542,3542,0752,0751,4801,4801,4801,4801,3941,3961,3971,3992,7422,7462,7492,7521,2101,2100000036,40936,40936,40936,40936,409000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,075
6,072
6,072
6,072
6,072
3,851
3,791
3,816
4,142
0
0
4,359
0
0
004,359004,1423,8163,7913,8516,0726,0726,0726,0722,075000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,912
9,536
9,536
9,536
9,536
10,599
0
0
0
0
0
0
0
0
0000000010,5999,5369,5369,5369,5363,912000000000000000000000000000000
> Total Stockholder Equity
0
0
0
-44,844
-45,645
-46,854
-46,302
-46,807
2,134
914
8,677
6,087
6,667
6,468
3,245
-329
-1,146
4,569
679
-1,927
5,278
13,548
11,100
8,936
10,039
8,472
5,212
6,622
9,318
7,798
5,961
7,000
12,685
10,454
17,348
9,225
9,225
11,258
10,521
11,408
10,156
13,642
8,104
6,110
6,1108,10413,64210,15611,40810,52111,2589,2259,22517,34810,45412,6857,0005,9617,7989,3186,6225,2128,47210,0398,93611,10013,5485,278-1,9276794,569-1,146-3293,2456,4686,6676,0878,6779142,134-46,807-46,302-46,854-45,645-44,844000
   Common Stock
0
0
0
2
107
107
2
2
64
65
77
77
83
90
96
101
109
172
172
173
173
424
434
438
456
457
30
41
46
46
46
56
71
71
126
127
127
127
11
18
19
69
77
77
777769191811127127127126717156464646413045745643843442417317317217210910196908377776564221071072000
   Retained Earnings Total Equity00000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
53
55
17
146
57
75
105
103
115
114
114
114
120
120
123
126
127
129
131
137
134
134
135
138
139
140
140
123
-1
10
-15
-60
0
-86
-59
-263
-183
-215
-226
-266
-183
-183-266-226-215-183-263-59-860-60-1510-11231401401391381351341341371311291271261231201201141141141151031057557146175553000
   Capital Surplus 00000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
10,190
10,244
9,778
9,995
9,997
59,117
60,397
60,976
71,151
74,167
77,786
77,933
78,048
80,143
89,119
89,367
89,590
89,695
100,492
101,151
101,514
101,729
101,996
102,588
106,689
111,331
111,528
111,716
115,284
123,524
123,787
133,638
-86
133,918
135,634
142,739
146,035
146,683
152,744
153,001
153,192
153,192153,001152,744146,683146,035142,739135,634133,918-86133,638123,787123,524115,284111,716111,528111,331106,689102,588101,996101,729101,514101,151100,49289,69589,59089,36789,11980,14378,04877,93377,78674,16771,15160,97660,39759,1179,9979,9959,77810,24410,190000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-62
Gross Profit-62-62
 
Operating Income (+$)
Gross Profit-62
Operating Expense-8,628
Operating Income-8,690-8,690
 
Operating Expense (+$)
Research Development4,027
Selling General Administrative4,663
Selling And Marketing Expenses-62
Operating Expense8,6288,628
 
Net Interest Income (+$)
Interest Income176
Interest Expense-11
Other Finance Cost-3
Net Interest Income167
 
Pretax Income (+$)
Operating Income-8,690
Net Interest Income167
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-12,424-4,957
EBIT - interestExpense = -8,701
-12,424
-12,503
Interest Expense11
Earnings Before Interest and Taxes (EBIT)-8,690-12,412
Earnings Before Interest and Taxes (EBITDA)-8,628
 
After tax Income (+$)
Income Before Tax-12,424
Tax Provision-90
Net Income From Continuing Ops-12,744-12,514
Net Income-12,514
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses8,690
Total Other Income/Expenses Net-3,733-167
 

Technical Analysis of Kiora Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Kiora Pharmaceuticals Inc. The general trend of Kiora Pharmaceuticals Inc is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Kiora Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Kiora Pharmaceuticals Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.511 < 0.519 < 0.5339.

The bearish price targets are: 0.475 > 0.462.

Tweet this
Kiora Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Kiora Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Kiora Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Kiora Pharmaceuticals Inc. The current macd is -0.03064612.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Kiora Pharmaceuticals Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Kiora Pharmaceuticals Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Kiora Pharmaceuticals Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Kiora Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartKiora Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Kiora Pharmaceuticals Inc. The current adx is 15.68.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Kiora Pharmaceuticals Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Kiora Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Kiora Pharmaceuticals Inc. The current sar is 0.454878.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Kiora Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Kiora Pharmaceuticals Inc. The current rsi is 39.11. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Kiora Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartKiora Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Kiora Pharmaceuticals Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Kiora Pharmaceuticals Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Kiora Pharmaceuticals Inc Daily Stochastic Oscillator ChartKiora Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Kiora Pharmaceuticals Inc. The current cci is -133.04103207.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Kiora Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartKiora Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Kiora Pharmaceuticals Inc. The current cmo is -25.16822283.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Kiora Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartKiora Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Kiora Pharmaceuticals Inc. The current willr is -84.70089995.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Kiora Pharmaceuticals Inc Daily Williams %R ChartKiora Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Kiora Pharmaceuticals Inc. The current atr is 0.05851344.

Kiora Pharmaceuticals Inc Daily Average True Range (ATR) ChartKiora Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Kiora Pharmaceuticals Inc. The current obv is 152,530,742.

Kiora Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartKiora Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Kiora Pharmaceuticals Inc. The current mfi is 54.64.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Kiora Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartKiora Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Kiora Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-14WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-17CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-30WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-17BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-25WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Kiora Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Kiora Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.109
Ma 20Greater thanMa 500.563
Ma 50Greater thanMa 1000.606
Ma 100Greater thanMa 2000.594
OpenGreater thanClose0.491
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Kiora Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Kiora Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Kiora Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Kiora Pharmaceuticals Inc

I send you an email if I find something interesting about Kiora Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Kiora Pharmaceuticals Inc.

Receive notifications about Kiora Pharmaceuticals Inc in your mailbox!